Search results
Added:
1 year ago
ECO 2024 — Dr Donna H Ryan (Pennington Biomedical Research Center, US) joins us to discuss the first sub-analysis of the landmark SELECT trial (NCT03574597, Novo Nordisk).In this study, investigators looked at long-term weight loss with semaglutide 2.4 mg compared to a placebo among 17,604 participants. In SELECT, at 208 weeks, semaglutide produced clinically significant weight loss compared to…
View more
Added:
1 year ago
ACC.24 — Dr Harold E Bays, Science Officer for the Obesity Medicine Association, a member of the Board of Trustees of the Obesity Medicine Association, and a member of the Board of Directors of the American Society of Preventive Cardiology, joins us to highlight key information regarding weight loss medications in 2024.Support: This is an independent interview conducted by Radcliffe Cardiology…
View more
Added:
2 years ago
Radcliffe Medical Education bring together a distinguished panel of globally renowned experts who provide guidance on navigating the ever-changing landscape of obesity and metabolic health management.
Under the chairmanship of Prof Jason Halford(University of Leeds, UK), the panel includingDr Lee Kaplan(Obesity, Metabolism and Nutrition Institute, Massachusetts General Hospital, US),Dr…
View more
Added:
7 months ago
ADA 25 - PATHWEIGH roadmap for implementing weight management into primary care eliminated a population weight gain trajectory.Dr Leigh Perreault (University of Colorado Anschutz Medical Campus, US) joins us remotely to discuss the PATHWEIGH trial, which investigated a process of care to facilitate and prioritize weight management in a primary care setting. PATHWEIGH focused on reducing excess…
View more
Added:
1 year ago
ECO 2024 — Prof Barbara McGowan (Guy's and St Thomas' Hospital & King's College, UK) joins us to discuss the findings from the STEP 10 trial (NCT05040971, Novo Nordisk).This Phase 3 randomised clinical trial investigated the efficacy and safety of subcutaneous semaglutide 2.4 mg (GLP-1 RA) in 181 participants with obesity (BMI greater than or equal to 30.0 kg/m^2) and prediabetes. The primary…
View more
Added:
7 months ago
New York Valves 25 - A substudy of TRISCEND II investigating the effect of transcatheter tricuspid valve replacement (TTVR) on preference-weighted health status showed significant benefits in patients who received TTVR.We are joined by Dr Suzanne Arnold (Saint Luke's Mid America Heart Institute, US) to discuss the findings from a substudy of the TRISCEND II trial, which aimed to create an…
View more
Added:
1 month ago
Jason Halford
Research Area(s) / Expertise:
Job title: Head of the School of Psychology
Author
Added:
6 months ago
Source:
Radcliffe CVRM
A new study has explored the underlying mechanisms by which semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1RA), improves outcomes in patients with metabolic dysfunction-associated steatohepatitis (MASH).¹ The research, which combined analysis of a phase 2 clinical trial with preclinical models, identified a unique proteomic signature associated with treatment and suggests that…
View more
Added:
7 months ago
ADA 2025 - Once-monthly MariTide treatment demonstrates around 15% average weight reduction at 52 weeks in patients with obesity, with or without type 2 diabetes.We are joined by Dr Harold Bays (L-MARC Research Center, Louisville, US) to discuss a 52-week, placebo-controlled, phase 2 randomised study (NCT05669599) investigating the efficacy, safety and tolerability of different doses of once…
View more